S286: LONG-TERM EFFICACY AND SAFETY RESULTS FROM AN ONGOING OPEN-LABEL PHASE 2 STUDY OF PARSACLISIB FOR THE TREATMENT OF AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)
W. Barcellini,
I. Murakhovskaya,
L. Terriou,
F. Pane,
A. Patriarca,
K. Butler,
S. Moran,
S. Wei,
U. Jäger
Affiliations
W. Barcellini
1 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
I. Murakhovskaya
2 Albert Einstein College of Medicine/Montefiore Medical Center Bronx, New York, United States of America
L. Terriou
3 Univ. Lille, Inserm, CHU Lille, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), INFINITE – Institute for Translational Research in Inflammation, Lille, France
F. Pane
4 University of Naples “Federico II”, Naples
A. Patriarca
5 University of Eastern Piedmont and AOU “Maggiore della Carità”, Novara, Italy
K. Butler
6 Incyte Corporation, Wilmington, United States of America
S. Moran
6 Incyte Corporation, Wilmington, United States of America
S. Wei
6 Incyte Corporation, Wilmington, United States of America
